Private Equity Investments in Public Healthcare Companies
Private equity firms currently hold 221 positions in publicly-traded healthcare companies. The majority of these are pharmaceutical companies, followed by biotechnology companies.
Pharma
Top private equity firms investing in public Pharmaceutical companies
- Foresite Capital – 34 positions
- OrbiMed Advisors – 19 positions
- Aisling Capital – 14 positions
- TPG – 5 positions
- Essex Woodlands – 5 positions
Examples: Private Equity Investments in public Pharmaceutical companies
- Foresite Capital invested in SAGE Therapeutics (SAGE). Market Cap = $6.8 billion
- OrbiMed Advisors invested in CTI BioPharma (CTIC). Market Cap = $113 million
- Aisling Capital invested in GTX (GTXI). Market Cap = $276 million
- TPG invested in Collegium Pharmaceutical (COLL). Market Cap = $579 million
- Essex Woodlands invested in Revance Therapeutics (RVNC). Market Cap = $1.1 billion
BioTech
Top private equity firms investing in public Biotechnology companies
- Foresite Capital – 17 positions
- OrbiMed Advisors – 6 positions
- Polaris Partners – 5 positions
- Aisling Capital – 4 positions
- HBM Healthcare Investments – 2 positions
Examples: Private Equity Investments in public Biotechnology companies
- Foresite Capital invested in Jounce Therapeutics (JNCE). Market Cap = $471 million
- OrbiMed Advisors invested in Xtant Medical (XTNT). Market Cap = $10.7 million
- Polaris Partners invested in Editas Medicine (EDIT). Market Cap = $994 million
- Aisling Capital invested in Audentes Therapeutics (BOLD). Market Cap = $852 million
- HBM Healthcare Investments invested in Neurocrine Biosciences (NBIX). Market Cap = $6.2 billion
Related: Read our broader study of Private Equity Investments in Public Companies.